tiprankstipranks
In this article:
Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

In this article:
In this article:

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Mesa Laboratories (MLABResearch Report), Kezar Life Sciences (KZRResearch Report) and LAVA Therapeutics (LVTXResearch Report) with bullish sentiments.

Mesa Laboratories (MLAB)

Jefferies analyst Brandon Couillard maintained a Buy rating on Mesa Laboratories today and set a price target of $265.00. The company’s shares closed last Friday at $181.56, close to its 52-week low of $178.32.

According to TipRanks.com, Couillard is a top 100 analyst with an average return of 23.1% and a 69.8% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Nautilus Biotechnolgy, Bio-Rad Laboratories, and Thermo Fisher.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mesa Laboratories with a $253.33 average price target.

See today’s best-performing stocks on TipRanks >>

Kezar Life Sciences (KZR)

Jefferies analyst Maury Raycroft maintained a Buy rating on Kezar Life Sciences today and set a price target of $20.00. The company’s shares closed last Friday at $5.02, close to its 52-week low of $4.31.

According to TipRanks.com, Raycroft is a 1-star analyst with an average return of -2.0% and a 34.4% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Aurinia Pharmaceuticals, and Reata Pharmaceuticals.

Kezar Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $18.33.

LAVA Therapeutics (LVTX)

In a report released today, Chris Howerton from Jefferies maintained a Buy rating on LAVA Therapeutics, with a price target of $23.00. The company’s shares closed last Friday at $2.55, close to its 52-week low of $2.51.

According to TipRanks.com, Howerton is ranked 0 out of 5 stars with an average return of -20.9% and a 25.1% success rate. Howerton covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Applied Molecular Transport, and Finch Therapeutics Group.

LAVA Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $22.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MLAB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed